$1.75
+0.11%Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Chief Business Officer
Chief Financial Officer & Principal Accounting Officer
Chief Human Resources Officer
Chief Legal & Administrative Officer
Compensation
$315,000
Chief Operationg & Development officer
Compensation
$696,451
Chief Quality Officer
Chief Scientific Officer
Chief Technical Operations Officer
Head of Investor Relations
President
Compensation
$876,636
During the last 12 months, insiders have purchased $15.00M and sold $390K worth of NMRA shares, resulting in $14.61M of net buying activity.
0
0.00
0
0.00
+0
+$0
0
0.00
23.4K
82.59K
-83K
-$83K
5.7M
15.00M
114.7K
307.02K
+14.7M
+$14.69M
0
0.00
0
0.00
+0
+$0
Burow Kristina
Director, 10 Percent Owner:
$5.00M
Arch Venture Partners X, Llc
10 Percent Owner
$5.00M
Arch Venture Partners Xii, Llc
10 Percent Owner
$5.00M
Aurora Daljit Singh
Officer: See Remarks
$329K
Berns Paul L
Director, Officer: See Remarks
$34K
Pinto Joshua
Officer: President
$21K
Milligan Michael Lee
Officer: See Remarks
$5K
Strong bullish signal with $14.61M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
NMRA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 27, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 13, 2024 | 2024 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.